ALK (I1171N/D1203N)
Sign in to save this workspaceALK · Variant type: compound · HGVS: p.I1171N;p.D1203N
Components
p.I1171Np.D1203N
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 99.0% | 1.0% | 88.97 |
| 2 | Repotrectinib | 97.1% | 2.9% | 84.21 |
| 3 | Sunitinib | 68.6% | 31.4% | 91.73 |
| 4 | Vandetanib | 5.1% | 94.9% | 95.74 |
| 5 | Canertinib | 3.4% | 96.6% | 96.49 |
| 6 | Abemaciclib | 0.0% | 100.0% | 91.48 |
| 7 | Inavolisib | 0.0% | 100.0% | 100.00 |
| 8 | Acalabrutinib | 0.0% | 100.0% | 99.50 |
| 9 | Capivasertib | 0.0% | 100.0% | 96.48 |
| 10 | Remibrutinib | 0.0% | 100.0% | 99.50 |
| 11 | Darovasertib | 0.0% | 100.0% | 96.99 |
| 12 | Erlotinib | 0.0% | 100.0% | 99.75 |
| 13 | Palbociclib | 0.0% | 100.0% | 98.75 |
| 14 | Cobimetinib | 0.0% | 100.0% | 100.00 |
| 15 | Quizartinib | 0.0% | 100.0% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 99.0% | 99.5% | -0.5% |
| Repotrectinib | 97.1% | 99.4% | -2.3% |
| Sunitinib | 68.6% | 87.7% | -19.1% |
| Vandetanib | 5.1% | — | — |
| Canertinib | 3.4% | — | — |
| Abemaciclib | 0.0% | — | — |
| Inavolisib | 0.0% | — | — |
| Acalabrutinib | 0.0% | — | — |
| Capivasertib | 0.0% | — | — |
| Remibrutinib | 0.0% | — | — |
| Darovasertib | 0.0% | — | — |
| Erlotinib | 0.0% | — | — |
| Palbociclib | 0.0% | — | — |
| Cobimetinib | 0.0% | — | — |
| Quizartinib | 0.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.9ms